The histological findings were evaluated by three blinded, experienced liver-specific pathologists and were validated by discussion. Predictive variables associated with LY2157299 in vitro each stage of liver fibrosis were assessed using multivariate analyses. The diagnostic performances of the markers were expressed as diagnostic specificity, sensitivity, and area under the receiving operator characteristic (AUROC) curve. The AUROC curve values for predicting the stage of fibrosis of serum WFA+-M2BP were compared with five other indicators (i.e., platelets, hyaluronic acid, AST/ALT ratio, AST-to-platelet ratio index, and FIB-4 index). Results:
The serum WFA+-M2BP value in patients with stage 0 (n = 35), stage 1 (n =
113), stage 2 (n = 49), stage 3 (n = 41), and stage 4 (n = 51) fibrosis had cutoff indexes of 0.57, 0.70, 1.02, 1.57, and 2.96, respectively. All pairs of groups differed significantly from each other according to the Steel-Dwass test. Multivariate regression analysis showed that the serum WFA+-M2BP values predicted the stage of fibrosis (> stage 2). The AUROC curve, sensitivity, and specificity of selleckchem serum WFA+-M2BP were 0.876, 85.9%, and 74.6% for severe fibrosis, respectively, (> stage 3) and 0.879, 74.6%, and 87.0%, for cirrhosis, respectively. When compared with the other surrogate markers and scoring systems, serum WFA+-M2BP had the greatest AUROC curve for diagnosing severe fibrosis and cirrhosis. find more Conclusions: The measurement of serum WFA+-M2BP values based on glycan-based immunoassay provides an accurate and reliable method for assessing the stage of liver fibrosis in patients with NAFLD. This method appears quite
promising as a means for evaluating the natural course of the disease, therapeutic effects, and the suitability of liver biopsy. Disclosures: Michiie Sakamoto – Grant/Research Support: MSD, Canon The following people have nothing to disclose: Masanori Abe, Teruki Miyake, Atsushi Kuno, Yasuharu Imai, Yoshiyuki Sawai, Keisuke Hino, Yuichi Hara, Shuhei Hige, Masaaki Korenaga, Yoichi Hiasa, Masashi Mizokami, Hisashi Narimatsu Background and Objectives: In our animal studies, we showed that bone marrow cells (BMCs) infused via a peripheral vein efficiently repopulate the cirrhotic liver and produce collage-nases, resulting in reduced liver fibrosis, elevated serum albumin levels, and a significant increase in survival. We also confirmed that frequent BMC infusion contributed to suppression of tumor initiation in hepatocarcinogenic cirrhotic mice. Based on these results, we started “Autologous bone marrow cell infusion therapy” for liver cirrhotic patients as liver regeneration therapy using non-cultured autologous whole BMCs, and subsequently reported its safety and efficacy.